摘要
目的本研究旨在观察强化阿托伐他汀联合氨氯地平治疗冠状动脉慢血流的临床效果并探讨可能的机制。方法将诊断为冠状动脉慢血流患者分为干预组(36例)和对照组(32例),干预组患者给予阿托伐他汀40 mg/d+氨氯地平5 mg/d,对照组患者仅予安慰剂,两组均随访6个月,比较两组患者胸痛频次、冠状动脉血流状况、血浆内皮型一氧化氮合酶(e NOS)、超敏C反应蛋白(hs-CRP)及白细胞介素6(IL-6)水平变化。结果 68例患者完成本研究并获得有效节点数据,干预组患者胸痛频次较对照组明显减少,冠状动脉慢血流状况显著改善,e NOS水平显著上升,hs-CRP及IL-6水平显著下降(P<0.05)。结论强化阿托伐他汀联合氨氯地平治疗可以显著改善患者胸痛发作及冠状动脉血流状况,其机制可能与药物联合治疗保护冠状动脉血管内皮功能及抑制体内炎性反应有关。
Objective To investigate the effects of intensive atorvastatin combined with amlodipine in the treatment of coronary slow flow（CSF） and to explore the potential mechanism of therapeutic effect. MethodPatients with CSF were randomly assigned into intervention group（36 cases, atorvastatin 40 mg/d ＋ amlodipine 5 mg/d） and control group（32 cases, placebo）. The frequency of angina and TIMI frame counts were observed before and after 6-month treatment. Meanwhile, plasma samples from CSF patients were assayed for endothelial nitric oxide synthase（e NOS）, high sensitivity C-reactive protein（hs-CRP） and interleukin-6（IL-6）. ResultThere were significant differences in the frequency of angina and TIMI frame counts between the two groups（P〈0.05）. The levels of e NOS increased notably in intervention group, while the expression of hs-CRP and IL-6 decreased sharply compared with placebo group（P〈0.05）. Conclusion Intensive atorvastatin combined with amlodipine in the treatment of CSF can provide the better therapeutic effects, the mechanism may be related to drug treatment to protect coronary artery endothelial function and inhibit the inflammatory reaction in vivo.
出处
《中国医学前沿杂志（电子版）》
2015年第11期117-120,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
